The invention relates to tumor-specific binding proteins and all uses thereof. In particular, the invention relates to antibodies or antibody fragments specific for antigens or molecules on cancer cells (CD166) and to methods of use thereof. Binding proteins comprising specific heavy and light chain CDRs are disclosed wherein the binding protein shows a measurable or significant binding to breast cancer cell line MDA-MB 231 but shows insignificant or unmeasurable binding to granulocytes or peripheral blood lymphocytes (PBLs).